Inhaled treatments in cystic fibrosis: What's new in 2013?;Mucoviscidose et traitements inhalés: quoi de neuf en 2013?

Revue des Maladies Respiratoires

Volumn 31, Issue 4, 2014, Pages 336-346

  Dubus, J C ^a   Bassinet, L ^b   Chedevergne, F ^c   Delaisi, B ^d   Desmazes Dufeu, N ^e   Reychler, G ^f   Vecellio, L ^g  

^a TIMONE HOSPITAL   (France)

^b CENTRE HOSPITALIER INTERCOMMUNAL DE CRÉTEIL   (France)

^c HÔPITAL NECKER ENFANTS MALADES   (France)

^d HÔPITAL ROBERT DEBRÉ   (France)

^e HÔPITAL NORD   (France)

^f CLINIQUES UNIVERSITAIRES SAINT LUC   (Belgium)

^g UNIVERSITÉ DE TOURS   (France)

Author keywords

Antibiotics; Cystic fibrosis; Inhalation devices; Mucolytic agents; Nebulization

Indexed keywords

AZTREONAM; COLISTIN; MANNITOL; SODIUM CHLORIDE; TOBRAMYCIN; AEROSOL; ANTIINFECTIVE AGENT; EXPECTORANT AGENT; POWDER;

CYSTIC FIBROSIS; DRY POWDER INHALER; HUMAN; INHALATIONAL DRUG ADMINISTRATION; NEBULIZATION; NEBULIZER; REVIEW; AEROSOL; CONTRAINDICATIONS; ECONOMICS; EQUIPMENT DESIGN; FRANCE; HEALTH CARE DELIVERY; POWDER;

ADMINISTRATION, INHALATION; AEROSOLS; ANTI-BACTERIAL AGENTS; CYSTIC FIBROSIS; DRY POWDER INHALERS; EQUIPMENT DESIGN; EXPECTORANTS; FRANCE; HEALTH SERVICES ACCESSIBILITY; HUMANS; MANNITOL; NEBULIZERS AND VAPORIZERS; POWDERS; SALINE SOLUTION, HYPERTONIC;

EID: 84900863789     PISSN: 07618425     EISSN: 17762588     Source Type: Journal    
DOI: 10.1016/j.rmr.2013.12.001     Document Type: Review

References (41)

1. Geller DE, Weers J, Heuerding J. Development of an inhaleddry-powder formulation of tobramycin using PulmoSphereTMtechnology. J Aerosol Med Pulm Drug Deliv 2011;24: 175-82.
2. Tiddens HA, Geller DE, Challoner P. Effect of dry powder inha-ler resistance on the the inspiratory flows and volumes ofpatients with cystic fibrosis of six years and older. J AerosolMed 2006;19: 456-65.
3. Diot P, Palmer LB, Smaldone A, et al. RhDNase I aerosol deposi-tion and related factors in cystic fibrosis. Am J Respir Crit CareMed 1997;156: 1662-8.
4. Hakkinen AM, Uusi-Heikkila H, Jarvinen M, et al. The effectof breathing frequency on deposition of drug aerosol usingan inhalation-synchronized dosimeter in healthy adults. ClinPhysiol 1999;19: 269-74.
5. Brand P, Meyer T, Haussermann S, et al. Optimum peripheraldrug deposition in patients with cystic fibrosis. J Aerosol Med 2005;18: 45-54.
6. Erzinger S, Schueepp KG, Brooks-Wildhaber J, et al. Facemasksand aerosol delivery in vivo. J Aerosol Med 2007;20:S78-83.
7. Alton EW, Boyd AC, Cheng SH, et al. A randomised, double-blind, placebo-controlled phase IIB clinical trial of repeatedapplication of gene therapy in patients with cystic fibrosis.Thorax 2013;68: 1075-7.
8. Denyer J, Prince I, Dixon E, et al. Evaluation of the target inha-lation mode (TIM) breathing maneuver in simulated nebulizertherapy in patients with cystic fibrosis. J Aerosol Med PulmDrug Deliv 2010;23:S29-36.
9. Brand P, Schulte M, Wencker M, et al. Lung depositionof inhaled alpha1-proteinase inhibitor in cystic fibrosis andalpha1-antitrypsin deficiency. Eur Respir J 2009;34: 354-60.
10. Brand P, Friemel I, Meyer T, et al. Total deposition of therapeu-tic particles during spontaneous and controlled inhalations. JPharm Sci 2000;89: 724-31.
11. Brand P, Beckmann H, Maas EM, et al. Peripheral deposition ofalpha1-protease inhibitor using commercial inhalation devices.Eur Respir J 2003;22: 263-7.
12. Kohler E, Sollich V, Schuster-Wonka R, et al. Lung depositionafter electronically breath-controlled inhalation and manuallytriggered conventional inhalation in cystic fibrosis patients. JAerosol Med 2005;18: 386-95.
13. Meyer T, Brand P, Herpich C, et al. Controlled inhalation ofbeta2-sympaticomimetics after bronchial provocation. Pneu-mologie 2003;57: 644-7.
14. Bakker EM, Volpi S, Salonini E, et al. Improved treatment res-ponse to dornase alfa in cystic fibrosis patients using controlledinhalation. Eur Respir J 2011;38: 1328-35.
15. Wark P, McDonald VM. Nebulised hypertonic saline for cysticfibrosis. Cochrane Database Syst Rev 2009;2:CD001506.
16. Reeves EP, Williamson M, O'Neill SJ, et al. Nebulized hypertonicsaline decreases IL-8 in sputum of patients with cystic fibrosis. Am J Respir Crit Care Med 2011;183: 1517-23.
17. Gould NS, Gauthier S, Kariya CT, et al. Hypertonic salineincreases lung epithelial lining fluid glutathione and thiocya-nate: two protectice CFTR-dependent thiols against oxidativeinjury. Respir Med 2010;11: 119.
18. Havasi V, Hurst CO, Briles TC, et al. Inhibitory effects ofhypertonic saline on P. aeruginosa motility. J Cyst Fibros 2008;7: 267-9.
19. Elkins MR, Robinson M, Rose BR, et al. A controlled trial of long-term inhaled hypertonic saline in patients with cystic fibrosis.N Engl J Med 2006;354: 229-40.
20. Dmello D, Nayak RP, Matuschak GM. Stratified assessment ofthe role of inhaled hypertonic saline in reducing cystic fibrosispulmonary exacerbations: a retrospective analysis. BMJ Open 2011;1:e000019.
21. Rosenfeld M, Ratjen F, Brumback L, et al. Inhaled hyperto-nic saline in infants and children younger than 6 years withcystic fibrosis: the ISIS randomized controlled trial. JAMA 2012;307: 2269-77.
22. Pezzulo AA, Stolz DA, Hornick DB, et al. Inhaled hyperto-nic saline in adults hospitalised for exacerbation of cysticfibrosis lung disease: a retrospective study. BMJ Open 2012;2:e000407.
23. Furnari ML, Termini L, Traverso G, et al. Nebulized hyper-tonic saline containing hyaluronic acid improves tolerabilityin patients with cystic fibrosis and lung disease comparedwith nebulized hypertonic saline alone: a prospective, ran-domized, double-blind, controlled study. Ther Adv Respir Dis 2012;6: 315-22.
24. Elkins MR, Tingpej P, Moriarty CP, et al. Tolerability of hyperto-nic saline when delivered rapidly via the e-Flow rapid nebulizerin subjects with cystic fibrosis [Abstract]. Pediatr Pulmonol 2006;41: 292.
25. Elkins M, Dentice R. Timinig of hypertonic saline inhalation forcystic fibrosis. Cochrane Database Syst Rev 2012;2:CD008816.
26. Baduredeen S, Ross-Russell R. Question 2: should hypertonicsaline be used in patients with cystic fibrosis who respond unsa-tisfactorily to recombinant deoxyribonuclease? Arch Dis Child 2010;95: 562-4.
27. Suri R, Metcalfe C, Wallis C, et al. Prediciting response torhDNase and hypertonic saline in children with cystic fibrosis.Pediatr Pulmonol 2004;37: 305-10.
28. Daviskas E, Anderson SD, Eberl S, et al. Inhalation of dry pow-der mannitol improves clearance of mucus in patients withbronchiectasis. Am J Respir Crit Care Med 1999;159: 1843-8.
29. Daviskas E, Anderson SD, Jaques A, et al. Inhaled mannitolimproves the hydration and surface properties of sputum inpatients with cystic fibrosis. Chest 2010;137: 861-8.
30. Teper A, Jaques A, Charlton B. Inhaled mannitol in patients withcystic fibrosis: a randomised open-label dose response trial. JCyst Fibros 2011;10: 1-8.
31. Bilton D, Robinson P, Cooper P, et al. Inhaled dry powder man-nitol in cystic fibrosis: an efficacy and safety study. Eur RespirJ 2011;38: 1071-80.
32. Aitken ML, Bellon G, De Boeck K, et al. Long-term inhaled drypowder mannitol in cystic fibrosis: an international randomizedstudy. Am J Respir Crit Care Med 2012;185: 645-52.
33. Retsch-Bogart GZ, Quittner AL, Gibson RL, et al. Efficacy andsafety of inhaled aztreonam lysine for airway Pseudomonas incystic fibrosis. Chest 2009;135: 1223-32.
34. McCoy KS, Quittner AL, Oermann CM, et al. Inhaled aztreo-nam lysine for chronic airway Pseudomonas aeruginosa in cysticfibrosis. Am J Respir Crit Care Med 2008;178: 921-8.
35. Oermann CM, Retsch-Bogart GZ, Quittner AL, et al. An 18-month study, AIR-CF3, of the safety and improvement inpulmonary function and respiratory symptoms with repeatedcourses of aztreonam for inhalation solution in patients withcystic fibrosis and airway Pseudomonas aeruginosa. Pediatr Pul-monol 2010;45: 1121-34.
36. Elborn JS, Henig NR. Optimal airway antimicrobial therapy forcystic fibrosis: the role of inhaled aztreonam lysine. ExpertOpin Pharmacother 2010;11: 1373-85.
37. Assael BM, Pressler T, Bilton D, et al. Inhaled aztreonam lysinevs. inhaled tobramycin in cystic fibrosis: a comparative efficacytrial. J Cyst Fibros 2012 [Epub ahead of print].
38. Schuster A, Haliburn C, Döring G, et al. Safety, efficacy andconvenience of colistimethate sodium dry powder for inha-lation (Colobreathe DPI) in patients with cystic fibrosis: arandomised study. Thorax 2013;68: 344-50.
39. Standaert TA, Speirs RJ, Rao N, et al. Young cystic fibrosispatients can effectively use a novel high-payload capsule-based dry powder inhaler with tobramycin powder forinhalation (TPI). Pediatr Pulmonol 2004;38: 284.
40. Konstan MW, Geller DE, Miníc P, et al. Tobramycin Inhala-tion powder for P. aeruginosa infection in cystic fibrosis: TheEVOLVE trial. Pediatr Pulmonol 2011;46: 230-8.
41. Konstan MW, Flume PA, Kappler M, et al. Safety, efficacy andconvenience of tobramycin inhalation powder in cystic fibrosispatients: the EAGER trial. J Cyst Fibros 2011;10: 54-61.